- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05287542
Hypnosis in Working Memory Rehabilitation
Releasing Residual Cognitive Capacity After Acquired Brain Injury: A Randomized Controlled Trial Using Hypnotic Suggestion in Rehabilitation of Working Memory
Study Overview
Status
Intervention / Treatment
Detailed Description
The potential impact of applying hypnosis in cognitive rehabilitation is substantial. Deficits in WM is one of the most common challenges after ABI and plays a critical role in post-injury outcome. Still, state-of-the-art approaches within WM rehabilitation have not been able to produce significant effects that transfer to real- life functioning for the affected patients. Building on the strong results of hypnosis on WM in ABI from a Danish single trial, we will aim at replication and expansion of the study in a Norwegian context. The initial study will be expanded in terms of number of participants, injury-characteristics will be included, outcome measures of relevance to real-life functioning, and underlying mechanisms of change will be explored. Self-efficacy is generalizable by nature (self-efficacy gained from mastery experiences in one situation generalizes to others), thus WM rehabilitation effects are expected to generalize and transfer to other domains in daily life.
This randomized controlled trial (RCT) aims to evaluate the effectiveness of hypnosis in WM rehabilitation in ABI patients. Ninety patients will be recruited from Sunnaas Rehabilitation Hospital. Inclusion criteria are non-progressive ABI, minimum 12 months post- injury, ongoing WM deficits and age between 18 and 67 years. Patients will be randomized to either a) an intervention group receiving four weekly 60 min. sessions with induction and hypnosis, b) an active control group receiving four weekly 60 min. sessions of induction and mindfulness, or c) a passive control group without intervention. The targeted procedure consists of suggestions about enhancing WM functions through the instantiation of preinjury WM ability in the present using age regression and visualizations of brain plasticity. The non- targeted suggestions contain no explicit mentioning of ABI or WM-related abilities. Each participant will be assessed at baseline, immediately after intervention and six months after baseline. Primary outcome is WM as measured by neuropsychological tests as well as self- and informant reported WM capacity. Secondary outcomes include self-rated ABI related symptoms, self-efficacy, mental health, and global outcome. A process evaluation will be carried out to evaluate treatment experience,
Rehabilitation of impaired WM after ABI has hitherto yielded limited clinical effects, and clinical trials of new interventions are thus warranted. Long-standing empirical evidence demonstrates that hypnosis is an effective therapeutic technique in a wide range of conditions, including in altering cognitive functions and improving WM in healthy adults, supported by imaging data. Recent exploratory research has suggested remarkable efficacy of hypnosis in improving WM in patients with ABI. However, these findings need replication in studies applying scientifically rigorous designs. If successful, our ambition is to provide recommendations and materials to implement hypnotic suggestion as an adjunct treatment following ABI in Norwegian rehabilitation clinics. Study findings may inform future studies exploring the use of clinical hypnosis in other areas of rehabilitation, such as mild TBI, and in other neurological conditions where WM deficit is prominent.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Marianne Løvstad, Profesor
- Phone Number: +4793452003
- Email: Marianne.Lovstad@sunnaas.no
Study Contact Backup
- Name: Line Sophie Eide, Cand.psyc
- Phone Number: +4797950051
- Email: Line.Eide@sunnaas.no
Study Locations
-
-
Viken
-
Nesoddtangen, Viken, Norway, 1453
- Recruiting
- Sunnaas rehabilitation hospital
-
Contact:
- Anne Catrine Martinsen, PhD
- Email: anne.catrine.traegde.martinsen@sunnaas.no
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- A documented non-progressive ABI, minimum 12 months post- injury and ongoing WM deficits by self-report and/or neuropsychological assessment
- The above mentioned patients have received multidisciplinary cognitive rehabilitation before participation
Exclusion Criteria:
- Patients with severe mental illness
- Patients progressive neurologic disease
- Patients with ongoing ICD-10 diagnosis of substance dependence
- Patients that lack Norwegian language skills
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Hypnotic suggestion
During the first phase of the study, two groups will receive identical hypnotic inductions followed by targeted suggestion for one group and non-targeted suggestion for the other.
The targeted procedure consists of suggestions about enhancing WM functions through the instantiation of preinjury WM ability in the present using age regression and visualizations of brain plasticity.
|
The intervention group will receive four weekly 60 min.
sessions with hypnosis treatment including induction followed by hypnotic suggestion.
|
ACTIVE_COMPARATOR: Mindfulness
The targeted procedure consists of suggestions about enhancing WM functions through the instantiation of preinjury WM ability in the present using age regression and visualizations of brain plasticity.
|
The active control group will receive four weekly 60 min.
sessions of induction and mindfulness-based instructions.
|
NO_INTERVENTION: No treatment
The passive control group receives no intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in WM on neuropsychological tests
Time Frame: Change from Baseline (T1) to immediately after the intervention period (T2) and 8 months after Baseline (T3)
|
Measured by the WM Index WAIS IV
|
Change from Baseline (T1) to immediately after the intervention period (T2) and 8 months after Baseline (T3)
|
Change in WM-related symptoms in everyday life
Time Frame: Change from Baseline (T1) to immediately after the intervention period (T2) and 8 months after Baseline (T3)
|
Assessed with the WM subscale from the Behavior Rating Inventory of Executive functioning Adult version (BRIEF-A) on a 3-point scale: Never a problem, sometimes a problem or often a problem.
Higher scaled score indicates higher level of problems with WM.
|
Change from Baseline (T1) to immediately after the intervention period (T2) and 8 months after Baseline (T3)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in cognitive composite score as seen on neuropsychological tests
Time Frame: Change from Baseline (T1) to immediately after the intervention period (T2) and 8 months after Baseline (T3)
|
Measured by Trail Making A+B, D-KEFS CWIT 1-4, CVLT-II, WAIS IV Digit Symbol
|
Change from Baseline (T1) to immediately after the intervention period (T2) and 8 months after Baseline (T3)
|
Change in TBI related challenges in everyday life
Time Frame: Change from Baseline (T1) to immediately after the intervention period (T2) and 8 months after Baseline (T3)
|
Measured by the Patient Competency Rating Scale on a 5-point scale from 1 can't do it to 5: No problem to do it.
Higher total scaled score represents better every day functioning.
|
Change from Baseline (T1) to immediately after the intervention period (T2) and 8 months after Baseline (T3)
|
Change in self reported mental health
Time Frame: Change from Baseline (T1) to immediately after the intervention period (T2) and 8 months after Baseline (T3)
|
Measured with the Hopkins Symptom Checklist (HSCL) on a scale from 1 (not at all) to 4 (a lot).
Higher mean score reflects a higher level of emotional distress.
|
Change from Baseline (T1) to immediately after the intervention period (T2) and 8 months after Baseline (T3)
|
Change in quality of life
Time Frame: Change from Baseline (T1) to immediately after the intervention period (T2) and 8 months after Baseline (T3)
|
Assessed with Quality of Life After Brain Injury (QOLIBRI) on a satisfaction scale from 0 (not satisfied) to 5 (very satisfied).
Higher satisfaction indicates higher quality of life.
|
Change from Baseline (T1) to immediately after the intervention period (T2) and 8 months after Baseline (T3)
|
Changes in community integration
Time Frame: Change from Baseline (T1) to immediately after the intervention period (T2) and 8 months after Baseline (T3)
|
Assesed with Participation Assessment with Recombines Tools-Objective (PART-O) on a 5-point scale: None, 1-4 hours, 5-9 hours, 10-19 hours, 20-34 hours, 35 hours or more.
Higher mean scaled score indicates better community integration.
|
Change from Baseline (T1) to immediately after the intervention period (T2) and 8 months after Baseline (T3)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in ABI related self-efficacy
Time Frame: Change from Baseline (T1) to immediately after the intervention period (T2) and 8 months after Baseline (T3)
|
The tool to measure Traumatic Brain Injury Self-Efficacy is rated on a scale from 0 (very uncertain) to 10 (Very certain).
Higher total score on the questionnaire indicates higher TBI related self-efficacy.
|
Change from Baseline (T1) to immediately after the intervention period (T2) and 8 months after Baseline (T3)
|
Changes in WM self-efficacy
Time Frame: Change from Baseline (T1) to immediately after the intervention period (T2) and 8 months after Baseline (T3)
|
The Memory Self-Efficacy Questionnaire (MSEQ) is rated on a scale from 0 (never) to 12 (100% of the time).
Higher total scales score indicates higher WM self-efficacy.
|
Change from Baseline (T1) to immediately after the intervention period (T2) and 8 months after Baseline (T3)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Marianne Løvstad, Profesor, Sunnaas Rehabilitation Hospital and University of Oslo
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Hypnoseprosjektet
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Injuries
-
Eunice Kennedy Shriver National Institute of Child...CompletedTraumatic Brain Injuries
-
Technical University of MunichFederal Ministry of Defence (Germany); Bundesministerium der VerteidigungRecruitingTraumatic Brain InjuriesFrance, Germany
-
University of Colorado, DenverBinghamton University; Brooke Army Medical CenterRecruitingBrain ConcussionUnited States
-
University of Alabama at BirminghamCompletedTraumatic Brain InjuriesUnited States
-
Mosaic Life CareMissouri Western State UniversityTerminatedBrain Injuries | Brain Concussion | Athletic Injuries | Diffuse Axonal Injury | Injury, Brain, TraumaticUnited States
-
More FoundationElMindA Ltd; Riddell, LLC; Mimic SystemsUnknownAthletic Injuries | Concussion, BrainUnited States
-
Bayside HealthVictorian Trauma FoundationCompletedTraumatic Brain Injury | Multiple Trauma | Spinal InjuriesAustralia
-
La Trobe UniversityRecruitingAnterior Cruciate Ligament Injuries | Concussion, Brain | Musculoskeletal InjuryAustralia
-
Association de Recherche Bibliographique pour les...University of Cambridge; Centre Hospitalier Princesse Grace; Institut National...CompletedBrain Injuries | Sport Injury | Concussion, BrainMonaco
-
CentraCareElectroCore INCCompletedTraumatic Brain Injury | Acute Brain InjuriesUnited States
Clinical Trials on Hypnotic suggestion
-
Hospital de Clinicas de Porto AlegreRecruitingFibromyalgia | Hypnosis | Transcranial Direct Current StimulationBrazil
-
Mayo ClinicCompletedDepression | Cognitive Impairment | Anxiety | Post Traumatic Stress Disorder | Illness, CriticalUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Foundation MedicineCompletedMetastatic Breast CancerUnited States
-
Brigham and Women's HospitalOregon Health and Science University; Vanderbilt University; Geisinger ClinicCompletedMyocardial Infarction | Coronary Artery Disease | Smoking | Stroke | Hypertension | Chronic Obstructive Pulmonary Disease | Atrial Fibrillation | Asthma | Tuberculosis | Sleep Apnea | Sickle Cell Disease | Hyperlipidemia | Congestive Heart FailureUnited States
-
University of UtahCompleted
-
University of UtahCompleted
-
Universitaire Ziekenhuizen KU LeuvenKU Leuven; Research Foundation FlandersUnknown
-
National Taiwan University HospitalTerminatedOsteoporosis, PostmenopausalTaiwan
-
Trustees of Dartmouth CollegeNot yet recruiting
-
All India Institute of Medical Sciences, New DelhiUnknownEEG, Psychogenic Non Epileptic Events